摘要
目的 分析缺氧诱导因子-1α(hypoxia-inducible factor-1α,HIF-1α)、诱导型一氧化氮合酶(inducible nitric oxide synthase,iNOS)和促红细胞生成素(erythropoietin,EPO)在卵巢上皮性肿瘤组织中的表达变化及意义。方法 收集2017年8月至2020年12月于浙江省余姚市人民医院行手术切除并经病理证实的卵巢上皮性肿瘤和正常卵巢组织患者96例,其中正常卵巢组织患者21例(正常组),良性肿瘤患者26例(良性组),交界性肿瘤患者11例(交界组),恶性肿瘤患者38例(恶性组)。分析HIF-1α、iNOS和EPO在不同卵巢组织中的表达变化以及各指标对卵巢癌的预测价值。结果 正常组、良性组、交界组、恶性组的HIF-1α、iNOS和EPO蛋白表达阳性率逐渐升高(P <0.05),恶性组中不同临床分期、病理分级间HIF-1α、iNOS和EPO蛋白的表达差异均有统计学意义(P <0.05),其中Ⅲ/Ⅳ期、中低分化卵巢癌阳性率更高。HIF-1α、iNOS、EPO蛋白单一及联合对卵巢癌的阳性预测值分别为61.70%、70.00%、65.22%和82.76%,阴性预测值分别为81.63%、82.14%、84.00%和88.24%。结论 明确HIF-1α、iNOS和EPO在卵巢上皮性肿瘤组织中的表达情况,有助于监测肿瘤的发生、发展,对制定治疗方案、评估预后具有一定的指导意义。
Objective To analyze the expression and significance of hypoxia-inducible factor-1α(HIF-1α),inducible nitric oxide synthase(iNOS) and erythropoietin(EPO) in epithelial ovarian tumor tissues.Methods A total of 96 patients were collected,including 21 patients with normal ovarian tissues(normal group),26 patients with benign tumors(benign group),11patients with borderline tumors(borderline group),and 38 patients with malignant tumors(malignant group).The expression changes of HIF-1α,iNOS and EPO in different ovarian tissues and the predictive value of each index for ovarian cancer were analyzed.Results The positive rates of HIF-1α,iNOS and EPO protein expression in the normal,benign,borderline and malignant groups gradually increased(P<0.05),there was significant difference in the expression of HIF-1α,iNOS and EPO protein between different clinical stages and pathological grades of malignant tumors(P<0.05).The positive predictive value of HIF-1α,iNOS,and EPO proteins alone and in combination in predicting ovarian cancer was 61.70%,70.00%,65.22%,and 82.76%respectively,and the negative predictive value was 81.63%,82.14%,84.00%,and 88.24% respectively.Conclusion Defining the expression of HIF-1α,iNOS and EPO in epithelial ovarian tumor tissues can monitor the occurrence and development of tumors and has certain guiding significance for formulating treatment plans and evaluating prognosis.
作者
赵娜
苏雪锋
谷颖颖
ZHAO Na;SU Xuefeng;GU Yingying(Yuyao People’s Hospital,Zhejiang Yuyao 315400,China)
出处
《中国妇产科临床杂志》
CSCD
2023年第1期40-42,共3页
Chinese Journal of Clinical Obstetrics and Gynecology
基金
宁波市自然科学基金项目(2016A610026)。